key: cord-0693875-55l7gnry
authors: Sen, Debanjan; Debnath, Bimal; Debnath, Pradip; Debnath, Sudhan; Zaki, Magdi E. A.; Masand, Vijay H.
title: Identification of potential edible mushroom as SARS-CoV-2 main protease inhibitor using rational drug designing approach
date: 2022-01-27
journal: Sci Rep
DOI: 10.1038/s41598-022-05349-x
sha: 6f5493babed4479586fea9fa98159c031ad7e924
doc_id: 693875
cord_uid: 55l7gnry

Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is highly pathogenic to humans and has created health care threats worldwide. This urgent situation has focused the researchers worldwide towards the development of novel vaccine or small molecule therapeutics for SARS-CoV-2. Although several vaccines have already been discovered and are in use for the masses, no therapeutic medication has yet been approved by FDA for the treatment of COVID-19. Keeping this in view, in the present study, we have identified promising hits against the main protease (M(pro)) of SARS-CoV-2 from edible mushrooms. Structure-based virtual screening (VS) of 2433 compounds derived from mushrooms was performed with M(pro) protein (6LU7). Four promising hits, namely, Kynapcin-12 (M_78), Kynapcin-28 (M_82), Kynapcin-24 (M_83), and Neonambiterphenyls-A (M_366) were identified based on the result of docking, Lipinski’s rule, 100 ns molecular dynamics (MD) simulation and MM/PBSA binding free energy calculations. Finally, the inhibitory properties of these hits were compared with three known inhibitors, baicalein (1), baicalin (2), and biflavonoid (3). Data indicated that M_78, M_82 and M_83 compounds present in edible mushroom Polyozellus multiplex were potent inhibitors of M(pro)protein (6LU7). It could be concluded that edible mushroom Polyozellus multiplex has potential activity against SARS-CoV-2 infection and identified molecules could be further explored as therapeutic inhibitors against SARS-CoV-2.

protease (PL pro ), helicase, and RNA-dependent RNA polymerase (RdRp) 4 . Protein sequence alignment analyses of SARS-CoV-2 indicated that catalytic sites of the four SARS-CoV-2 enzymes which could serve as antiviral targets are highly conserved and show a total of 79.9% genomic similarity with SARS-CoV 5 . This attribute could be utilized to understand and inhibit the replication cycle of SARS-CoV-2. The non-structural proteins (nsPs), 3CL pro and PL pro , which are two important proteases, play a crucial role in the viral replication process through the extensive proteolysis of two replicase polyproteins, pp1a and pp1ab into 16 non-structural proteins (nsP1-nsP16) 6 . These nsPs are assembled and form the replication-transcription complex which regulates various functions of virus replication viz. replication of the viral genome, sub-genomic RNA processing, and packaging of the new virion 7 . Interrupting any replication process would become a potential molecular target to develop therapeutics against coronavirus.

The urgent need for drugs to treat COVID-19 has led scientists to focus on protease inhibitors as potential drugs for the treatment of COVID-19 patients. In this regard, M pro has been found to be highly sensitive, therefore, it has been considered as a key therapeutic target for the development of a drug against coronavirus 8, 9 . As a treatment strategy against COVID-19, a combination of anti-HIV protease drugs, lopinavir and ritonavir, was currently employed to treat the COVID-19 patients with mild and moderate infections 10, 11 . However, the patients' outcome treated with this combination suggested that the curative effect of these drugs is minimal with potentially toxic side effects that might be harmful to the patients 12 . Some other repurposed drugs are also currently used, taking the advantage of drug safety, to treat the COVID-19 patients as a short-term and non-specific solution [13] [14] [15] [16] . Identifying bioactive compounds from the natural sources, which could inhibit SARS-CoV-2 main protease, has been considered as an alternative approach to combat COVID-19. In silico techniques provide promising preliminary evidence for drug discovery in a shorter span of period. Recently, several researchers have focused on identifying potential biomolecules active against SARS-CoV-2 from natural sources by implication of in silico drugs designing approach [17] [18] [19] [20] [21] . This is because phytochemicals have been used as a good source of antiviral drugs in folk medicine to treat viral infections. Moreover, drug molecules identified from natural resources, especially plants have minimal side effects associated with them. Therefore, the development of more targeted inhibitors from natural sources could be an efficient therapeutic strategy to combat COVID- 19. Mushrooms are rich in low-calorie fibre, protein, health-boosting vitamins, and minerals. It is used as food due to its great taste and amazing health benefits worldwide. Mushrooms raised with exposure to ultraviolet light are a good source of Vitamin D 22 . There is a common belief that supplementation of mushrooms in dietary meals reduces the health care expenditure and remove the fear of the influenza outbreak 23 . Recent pharmacological studies indicated that mushrooms are an exceptional source of several bioactive molecules, possessing antiviral 24, 25 , anti-inflammatory 26, 27 , antioxidants, antifungal, anticancer, antibacterial, and inhibition of platelet aggregation activities 28 . Mushrooms exhibited strong anti-viral properties when used against influenza-A virus [29] [30] [31] , Dengue virus serotype 2 32 , HIV-1, HIV-2 33,34 , type-2 herpes simplex viruses 35 , pandemic H1N1 and human H3N2 36 . Many patients have continually suffered from inflammatory complications due to cytokine storms because of the elevated levels of ILs, IFN-γ, tumour necrosis factor α (TNF-α), interferon gamma-induced protein (IP10), and granulocyte colony-stimulating factor (GCSF) 37 . The major life-threatening event associated with the COVID-19 infection is cytokine storm 37 . More importantly, studies have shown that several edible mushrooms boost up immune responses by stimulating the immune effect or cells like cytotoxic T lymphocytes (TCL), T-cells, dendritic cells (DCs), natural killer cells, and macrophages, which further induced the expression and secretion of cytokines including interleukins (ILs) and interferon-gamma (INF-γ) 38, 39 . These exciting medicinal properties of mushrooms have led us to investigate their therapeutic potential against the COVID-19 40 . The main aim of the present study was to identify potential edible mushrooms with compounds having a high binding affinity towards SARS-CoV-2 M pro . Recently, Rangsinth et al. have carried out an in-silico study of mushroom compounds against the main protease of SARS-CoV-2 41 . However, they have investigated only 36 compounds that have been reported to possess anti-HIV protease properties. In our present study, we carried out a detailed investigation of 2433 mushroom compounds for their potential as SARS-CoV-2 main protease inhibitors using VS, MD simulation, Lipinski's rule, MM/PBSA binding free energy calculation, and comparison with known inhibitors. We observed that several phenolic compounds of mushrooms exhibited strong binding affinity with the main protease of SARS-CoV-2. Based on the results obtained, we believe that further in-vitro and in vivo studies of the reported compounds may provide more scientific information about the inhibitory properties of these mushrooms.

Data collection and preparation target protein. In the present study, a databank of 2433 compounds was retrieved from different mushrooms available in the literature [42] [43] [44] [45] [46] [47] and mushroom compounds from the food databank (https:// foodb. ca/). Structures of all compounds retrieved from the literature were drawn using ChemDraw Professional 15.1 and saved in the sdf format. After importing all the ligand files in the Maestro version 12.3 used under academic license, a single file was prepared. Then the prepared single-file was imported into the PyRx software tool. The UFF force field 48 was used to convert all the ligands in the pdbqt format, followed by energy minimization. The X-ray crystal structure of SARS-CoV-2 M pro (PDB ID: 6LU7, resolution: 2.16 Å) was downloaded from the RCSB protein databank (http:// www. rcsb. org/) 49, 50 . The previously prepared protein pdbqt file of M pro17 was used for the docking purpose in both AutoDock Vina (ADV) in PyRx and Auto-Dock 4.2 (AD), both are open-source software. The top fourteen hits resulted from virtual screening were again re-docked using AutoDock 4.2 51 software considering identical grid parameters.

Windows 10 Operating System supported by Intel i5 8600 K processor with 8 GB RAM. The grid dimension of the main protease was fixed by selecting active site amino acid residue information (HIS-41, MET-49, PHE-140, LEU-141, GLY-143, CYS-145, HIS-163, GLU-166, GLN-189). The grid centre coordinate of M pro were -10.88, 13.93, 68.21 along the X, Y and Z axis, respectively and grid size were 58, 68, 70 along X, Y and Z axis, respectively with grid spacing 0.375. The energy range was set at 4 and exhaustiveness was set at 8.0. For docking with protonated target, protonation was done by using H + + server version 3.2 (http:// bioph ysics. cs. vt. edu/H + +) 55 at pH = 6.5, internal dielectric = 10.0, external dielectric = 80.0 and salinity 0.15. The docking score of coligand (N3) was considered as the standard reference. Validation of the docking protocol is a crucial step before performing docking-based virtual screening. The docking protocol was validated by measuring the root mean square deviation (RMSD) using PyMOL 2.5. The compounds and co-ligand was prepared using the default parameters of PyRx. For calculation of RMSD, each docking poses of N3 generated during the docking program were superimposed on the native conformation of N3, using the "pair_fit" command in PyMOL software (http:// www. pymol. org). The output compound and protein in pdbqt format were imported in PyMOL 2.5 for visual inspection of binding poses, followed by the export of the protein-ligand complex in PDB. The protein-ligand complexes imported in ProteinsPlus server (https:// prote ins. plus) 56, 57 and their 2D interactions were analyzed.

Drug-likeness properties prediction. Nearly 40% of the identified candidate drugs fail in the clinical trials due to the poor ADME properties 58 . Therefore, prediction of the five physicochemical parameters such as molecular weight, number of H-bond acceptors, number of H-bond donors, molar refractivity, n-octanol/water partition coefficient, i.e., Lipinski's rule of five 59 of the selected hits was performed using publicly available online server SwissADME (http:// www. swiss adme. ch) 60 .

Molecular dynamic simulation protocol. All-atom molecular dynamics simulation (MDS) of the selected hits was conducted by Gromacs 2018.1 61 software supported by NVIDIA RTX 2070 GPU and Intel i7 990 k processor running over Linuxmint 19.3 Operating System (OS). The pdb2gmx program of the Gromacs 2018.1 package with Charmm36 62 force field was used to prepare the protein topology. Topology for each ligand was obtained from the SwissParamTool 63 , an online server-based parameterization program. After rejoining the protein and ligand topology, each system was solvated using TIP3P 64 water model into a (10Åx10Åx10Å) cubic box. Adequate numbers of Na + and Clions (0.15 M) were added to neutralize each solvated protein-ligand system. The steepest descent algorithm 65 was used to minimize each system with a maximum of 50,000 steps, and the force was set to less than10.0 kjole/mol. In the two-stage equilibration step, the 1st step is the NVT ensemble step in which the volume, temperature, and number of particles were kept constant and maintained for 2 ns. The 2nd step is the NPT ensemble step which has constant pressure along with equilibration of temperature and numbers of particles for 10 ns. For each equilibration step, 100 ns positional restraint of C α atoms were applied. Free movement of the solvent molecules was allowed to maintain the solvent equilibrium. The linear constraint solver algorithm 66 was used to constrain the covalent bonds of the system. The particle mesh Eshwald (PME) 67 method was applied for long-range electrostatic interaction setting cutoff of 1.2 nm and Fourier spacing of 1.2 nm. The V-rescale weak coupling method 68 was used to regulate the temperature (310.15 K) of the system. The Parrinello-Rahman method 69 was used to regulate 1 atm pressure, density, and total energy of the system. Each equilibrated system with acceptable geometry and solvent orientation was subjected to100 ns production run without setting any restraint followed by a 2 fs time step. The structural coordinates were recorded in every 2 ps interval. After the successful completion of the MDS, water and ions were stripped out, followed by PBC correction to refine the trajectories. From the refined trajectories, various parameters like root mean square deviation (RMSD) 70 , root mean square fluctuation (RMSF) 71 , the radius of gyration (Rg) 72 , and solvent accessible surface area (SASA) 73 that occurred in between ligand and protein were calculated considering co-crystal coordinates as a reference structure. The VMD1.9 74 program was used to visualize the trajectory and render images. Grace 5.1.25 software (https:// plasma-gate. weizm ann. ac. il/ Grace) was used as a plotting program. The stability of MD complexes was also evaluated using the centre of mass (CoM) distance.

Poisson-Boltzmann Surface Area (MM/PBSA) approach 75 . The g_mmpbsa script program 76 , a high throughput MM/PBSA calculation tool in Gromacs software, was used to perform MM/PBSA based binding free energy (∆G bind ) calculation [https:// rashm ikuma ri. github. io/g_ mmpbsa/ Tutor ial. html]. The g_mmpbsa script program, along with the APBS 1.4 program 77 was used to calculate the above terms. To perform the calculations mentioned above, snapshots of the last 10 ns frames were extracted from the total trajectory using the gmaxtrjconv command. The total 100 ns trajectory frames were supplied as an input for the g_mmpbsa program to calculate the binding energy.

Molecular docking and Lipinski's rule analysis. The M pro binding site interactions were assigned by importing the protein-ligand crystal structure in the ProteinsPlus server. The detailed active site interacting amino acid residues included LEU-4, GLY-143, HIS-163, GLU-166, and GLN-189. Therefore, a receptor grid box was prepared by selecting these active site amino acid residues. The RMSD value between the coligand and docking pose of the same was 1.47Å 17 . This value was less than 2.0 Å; therefore, the validation of the docking protocol was regarded to be successful. This indicates that there is little visible difference between the docked pose of colignd to the original crystallographic bound ligand pose. In the first step, databases containing 2433 numbers of compounds derived from mushrooms were docked with a ligand-free M pro active site using S1 ). In the crystal structure of SARS-CoV-2 M pro (PDB ID: 6LU7), the co-ligand (N3) of SARS-CoV-2 M pro was covalently bonded with CYS-145. This coligand was isolated from the protein-ligand crystal structure and re-docked into the active site of M pro . The docking score of co-ligand was − 7.2 kcal/mol and this value was used as a control value to reduce the chemical space after docking. The hits with the docking score of ≤ − 7.2 were selected as SARS-CoV-2 M pro inhibitors, source mushroom of the selected hits and trivial name of the hits have been summarized in Table 1 Along with docking score, interaction with crucial amino acid residues may be other important criteria in the selection of potential inhibitors. The ADV docking score of ten hits was less than the ADV docking score of known inhibitors 1 and was comparable to other known inhibitors 2 and 3 (Table S1) Fig. S4 .

Most of the top ten hit exhibited close (< 3.0 Å) hydrogen bond donor and hydrogen bond acceptor interactions. These short-distance interactions revealed the efficient binding affinity of the hits towards M pro . The detailed view of the 3D interaction often hits with SARS-CoV-2 M pro active site amino acid residues have been depicted in Fig. 1 . The molecular weights of all the top hits were in the range of 340.33-540.60. The acceptable range of molecular weight is ≤ 500. Therefore, the molecular weight of all the hits, except M_421 and M_505 were in the acceptable range. The number of hydrogen bond acceptors of all the hits was also in the range of 6-10. The acceptable range of this is ≤ 10. Therefore, the numbers of hydrogen bond acceptor values of all the selected hits were in the acceptable range. The range of hydrogen bond donor groups of all the selected hits was 4-5, and the acceptable range is ≤ 5; this property was also in the acceptable range.

For a drug-like molecule, the molar refractivity should be between 40 and 130, and here all the hits were in this range except M_421 and M_505. The n-octanol/water partition coefficient of all the hits should be ≤ 5; this value for all the selected hits was in the acceptable range in the present study. Therefore, the Lipinski rule of five dealing with 90% of the orally active drugs that have achieved phase II clinical status was obeyed by the hits M_78, M_82, M_83, M_88, M_111, M_112, M_201, M_366. Among the mushroom compounds based on docking score and interaction with amino acid residues, and drug-like charactersM_78, M_82, M_83, M_88, M_111, M_112, M_201, M_366 were selected for the MD simulation study. The physiochemical parameters of the top ten proposed inhibitors have been shown in Table 2 .

ulation is a widely accepted approach for predicting the protein-ligand complex's stability. The 100 ns atomistic MD simulation was performed to explore the dynamics property of each identified protein-ligand complex and was compared with the dynamic behavior of the ligand-free protein (LFP) co-crystalline inhibitor bound protein. The average values of every parameter calculated from molecular dynamics (MD) trajectories has been depicted in Table 3 .

The acceptable average RMSD value for globular protein is ≤ 3.0Å 80 . Nonetheless, lower RMSD values are ideally acceptable. It was observed that the protein backbones average RMSD of the selected M pro -ligand (M_78, M_82, M_83, M_111, M_112, M_201, M_366) were less than 3.0 Å ( Table 3 ). The average RMSD value exhibited by M_82, M_83, M_112, M_201, and M_366-protein systems was lower than the RMSD value of apo-protein.

The average RMSD of M_366-protein system was found to be ~ 1.98 Å, which was even lower than the standard inhibitor baicalein (~ 2.15 Å) 81 . The RMSD profile of the protein-M_88 system was > 3.0 Å. To compare the RMSD of the protein backbone profile of protein-ligand (M_78, M_82, M_83, M_366) system with apo-protein, the RMSD was plotted against time from the 100 ns molecular dynamics trajectories as shown in Fig. 2 . Similarly, the RMSD profiles of the protein-ligand (M_88, M_111, M_112, M_201) system has been depicted in Fig. S5 .

To analyze the fluctuation of the individual amino acid residues, the RMSF parameter was calculated for each protein-ligand complex system from the 100 ns molecular dynamics trajectories. Lower the RMSF value www.nature.com/scientificreports/ generalizes that after binding with the ligand, the fluctuation of the amino acid residues under consideration is reduced. These facts infer stable protein ligands binding, i.e., after binding with ligand, the fluctuation of residues is minimized. The amino acid residues THR-24 to GLN-192 lies in the binding site region of this protein. Amongst the residues, the HIS-41 and CYS-145 are the important residues that regulate the functionality of this protein 78 . The average RMSF value of each protein-ligand system has been mentioned in Table 3 . The plots of protein-ligand (M_78, M_82, M_83, M_366) system amino acid residues and RMSF has been shown in Fig. 3 . Similarly, the plots of protein-ligand (M_88, M_111, M_112, M_201) system residue vs RMSF have been depicted in Fig. S6 . It can be ascertained from Table 3 that each system other than M_88 and M_201 bound system, exhibited lower RMSF values in comparison to the apro-protein RMSF. In contrast, M_111 system depicted a slightly higher RMSF (~ 1.38 Å) value. Each residue of M_88 and M_201 system showed significantly higher RMSF profiles (Fig. S6) . Visual inspection of the trajectory concluded unacceptable changes taking place in the M_201 bound system during the 100 ns simulation time. The radius of gyration parameter further confirmed that event.

The parameter radius of gyration (Rg) furnishes information about the compactness of the protein. The higher value of Rg indicates that the protein changes its conformation of distortion during the simulation. The average Rg value of the protein-ligand (M_78, M_82, M_83, M_112, M_201, M_366) system was lower than the Rg value of apo-protein (Table 3 ). The average Rg value of the protein-ligand (M_78, M_82, M_83, M_201) system was lower than the Rg value of the standard inhibitor (22.44 Å) . The Rg profile of the hits M_78, M_82, M_83, and M_366 have been depicted in Fig. 4 and Rg profile of M_88, M_111, M_112, M_201 has been shown in Fig. S7 .

The protein-ligand system's solvent-accessible surface area parameter (SASA) was calculated for each protein-ligand system and plotted against the time in nanosecond. Considering that ligand binding is a solvent replacement process, the lower values of the SASA parameter indicate that the binding pocket is less solventexposed, and the ligand retains inside the binding pocket during the simulation. The average SASA value of the protein-ligand (M_78, M_82, M_83, M_201, M_366) system was lower than the SASA value of apo-protein ( Table 3 ). The average SASA value of the protein-ligand (M_82, M_201) system was lower than the SASA value of the standard inhibitor (1472Å2). The changes in SASA of M pro -ligand (M_78, M_82, M_83, M_366) systems and apo-protein during 100 ns simulation time have been shown in Fig. 5 . Similarly, the changes of SASA value of M_88, M_111, M_112, M_201 protein system have been shown in Fig. S8 . Each protein-ligand system, other than a protein-ligand system of M_111, and M_112, showed a lower average SASA value in comparison to the apo-proteins average SASA value (Table 3) . Nevertheless, the M_201 system exhibited a SASA value of ~ 1456.0Å 2 (lower than the apo-protein SASA value) which indicated that the ligand M_201 resided deeply into the binding pocket. However, this binding caused significant changes in the protein structure.

It was observed from Fig. S9 that the center of mass (CoM) distance for all the ligands resided within ~ 5.0 Å distance from the main protease binding site. The hits M_78 and M_82 consistently depicted ~ 2.0 Å distance from the protein binding pocket throughout the simulation. Ligand M_83 after ~ 85 th ns showed slightly higher displacement (~ 1.0 Å). After ~ 95 ns, the protein binding pocket M_83 distance reduced to ~ 2.2 Å. The M_366 after ~ 36 th ns showed a higher distance (~ 4.1 Å) from the protein binding pocket. However, after ~ 90 ns the distance reduced and stabilized at ~ 2.8 Å.

Binding free energy (∆G bind ). The MM/PBSA based binding free energy (∆G bind ) was calculated from the total 100 ns of the molecular dynamics trajectories. The ∆G bind of the standard inhibitor was − 180.50 kJ/mol, and the ∆G bind of M_78, M_201, and M_366 were − 193. 55, − 193.50 − 190 .10 kj/mol, respectively, greater than the ∆G bind of the standard inhibitor ( Table 3 ). The ∆G bind of M_82 was − 180.10 kj/mol, which was nearly the There have been a large report of antiviral activities of mushroom compounds (Table S3 ) and therefore identification of SARS-CoV-2 M pro inhibitors from reported mushroom compounds is of great interest. All the proposed compounds are novel, structurally diverse, and contain phenolic functional groups. Polyphenolic compounds perform a series of defensive activities in the human body. One of the important classes of phenolic compounds are flavonoids, which showed blocking potential against different viral proteins like M pro , PL pro , Spike against SARS-CoV and MARS-CoV 82 . Two flavones found in different plants, baicalein (1) and baicalin (2) (Fig. 6) , exhibited in vitro inhibition against SARS-CoV-2 M pro and IC 50 values, of which were 6.41 and 0.94 μM, respectively 83 . Another biflavonoids (3) found in Torreyanucifera showed inhibitory activity against SARS-CoVM pro and the IC 50 value of which was 8.3 μM 84 .

The ADV docking scores of the proposed hits were similar to the ADV docking score of the known inhibitors 1, 2, and 3 and the docking scores were -7.7, -8.6, and -8.7 kcal/mol, respectively (Table S1 ). The best docking poses of the proposed hits M_78, M_82, M_83, and M_366 in the active site superimposed on the two SARS-CoV-2 known inhibitors 1 and 2 have been shown in Fig. S3 . It was observed that the pyran ring, chromen-4-oneoxygen atom, pyran-1-oxygen atom of inhibitors 1 matched with the middle ring, an acetylated-phenolic-oxygen atom of the middle ring, and phenolic-OH of the middle ring, respectively, of hit M_78. Two rings of one of the benzofuran moiety; 5,6-dihydroxy group of one of the benzofuran moiety, furan oxygen of benzofuran moiety of hit M_82 matched with two rings of inhibitor 1; a 6,7-dihydroxy group of 1, and pyran-1oxygen of 1, respectively. The matching of the pharmacophore of hit M_83 was very close to M_82. The pyran ring, 6-hydroxyl group, and pyran-1-oxygen of compound 1 matched with one of the aromatic rings of dibenzofuran, 1-hydroxy group of dibenzofuran, and furan oxygen, respectively with M_366. The matching of the pharmacophores of the proposed hits in the most stable binding pose with standard inhibitor baicalein was again a piece of evidence in the favour of the potential of the selected hits, against SARS-CoV-2 M pro .

Based on the detailed in-silico studies, it can be concluded that compounds M_78, M_82, M_83, and M_366 showed docking scores greater than co-ligand and comparable docking scores with the two known SARS-CoV-2 inhibitors. The binding affinity of the hits M_78, M_82, M_83, M_366 against M pro protein of SARS-CoV-2 was also supported by all the MD parameters such as RMSD, RMSF, Rg, SASA, MM-PBSA binding energy (∆G bind ). Moreover, all the proposed hits obeyed the Lipinski rule of five and matches pharmacophores with known inhibitors in the active site. The promising hits Kynapcin-12 (M_78), Kynapcin-28 (M_82), Kynapcin-24 (M_83) are available in edible mushroom Polyozellus multiplex and another promising hit Neonambiterphenyls-A (M_366) is available in the poisonous mushroom Neonothopanus nimbi. The mushroom P. multiplex contains three potential hits which might be used as a remedy against COVID-19 after the appropriate biological screening. These novel phenolic scaffolds may be further developed as more potential SARS-CoV-2 inhibitors. 

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

A new coronavirus associated with human respiratory disease in China

Novel coronavirus that recently emerged in China

Recent discovery and development of inhibitors targeting coronaviruses

A pneumonia outbreak associated with a new coronavirus of probable bat origin

The SARS-coronavirus papain-like protease: Structure, function and inhibition by designed antiviral compounds

Viral macrodomains: Unique mediators of viral replication and pathogenesis

Candidate drugs against SARS-CoV-2 and COVID-19

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors

Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019

Why are lopinavir and ritonavir effective against the newly emerged coronavirus 2019? Atomistic insights into the inhibitory mechanisms

A trial of lopinavir-ritonavirses in adults hospitalized with severe COVID-19

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Therapeutic options for the 2019 novel coronavirus (2019-nCoV)

Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies

Chloroquine and hydroxychloroquine as available weapons to fight COVID-19

Identification of potential inhibitors of SARS-CoV-2 main protease and spike receptor from 10 important spices through structure-based virtual screening and molecular dynamic study

Possible SARS-Coronavirus-2 inhibitor revealed by simulated molecular docking to viral main protease and host toll-like receptor

In silico drug discovery of major metabolites from spices as SARS-CoV-2 main protease inhibitors

Rutin and flavone analogs as prospective SARS-CoV-2 main protease inhibitors: In silico drug discovery study

Natural-like products as potential SARS-CoV-2 M pro inhibitors: In-silico drug discovery

A review of Mushrooms as a potential source of dietary vitamin D

A hypothesis: Supplementation with mushroom-derived active compound modulates immunity and increases survival in response to influenza virus (H1N1) infection. Evid. Based Complement

Antiviral agents from fungi: Diversity, mechanisms and potential applications

Natural bioactive compounds from fungi as potential candidates for protease inhibitors and immunomodulators to apply for coronaviruses

Mushrooms: A potential natural source of anti-inflammatory compounds for medical applications

Anti-inflammatory properties of edible mushrooms: A review

The neurotrophic and neuroprotective potential of macrofungi

Maitake mushrooms (Grifolafrondosa) enhances antibody production in response to influenza vaccination in healthy adult volunteers concurrent with alleviation of common cold symptoms. Funct. Foods Health Dis

Inhibitory effect of TNF-alpha produced by macrophages stimulated with grifolafrondosa extract (ME) on the growth of influenza A/Aichi/2/68 virus in MDCK cells

Some Antiviral Mushrooms of Nepal

Anti-viral activity of culinary and medicinal mushroom extracts against dengue virus serotype 2: An in-vitro study

Antiviral agents with activity against human retroviruses

Anti-HIV1-protease activity of lanostanetriterpenes from the Vienamese mushroom Ganodermacolossum

Antiviral lanostanoidtriterpenes from the fungus Ganodermapfeifferi

The anti-Influenza virus effect of Phellinusigniarius extract

Antiinflammatory and immunomodulating properties of fungal metabolites

Immunomodulating and anticancer agents in the realm of macromycetes fungi (macrofungi)

SARS-CoV-2 infection: The role of cytokines in COVID-19disease

Natural bioactive compounds from fungi as potential candidates for protease inhibitors and immune modulators to apply for coronaviruses

Mushroom-derived bioactive compounds potentially serve as the inhibitors of SARS-CoV-2 main protease: An in silico approach

Bioactive phytochemical constituents of wild edible mushrooms from southeast Asia

Hericiumerinaceus, an amazing medicinal mushroom

The pharmacological potential of mushrooms

Two novel phenylacetoxylated p-terphenyls from Thelephoraganbajun Zang

Mushrooms: A source of exciting bioactive compounds

New p-terphenyl and benzoquinone metabolites from the bioluminescent mushroom Neonothopanusnambi

UFF, a full periodic table force field for molecular mechanics and molecular dynamics simulations

Structure of M pro from SARS-CoV-2 and discovery of its inhibitors

The crystal structure of COVID-19 main protease in complex with an inhibitor N3

AutoDock 4 and AutoDockTools4: Automated docking with selective receptor flexibility

Docking and scoring in virtual screening for drug discovery: Methods and applications

Auto Dock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading

Small-molecule library screening by docking with PyRx

H++ 3.0: Automating pK prediction and the preparation of biomolecular structures for atomistic molecular modeling and simulation

Fast automated placement of polar hydrogen atoms in protein-ligand complexes

Protoss: A holistic approach to predict tautomers and protonation states in proteinligand complexes

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules

Gromacs: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. Software X 1-2, 19-25

CHARMM36 all-atom additive protein force field: Validation based on comparison to NMR data

SwissParam: A fast force field generation tool for small organic molecules

Comparison of simple potential functions for simulating liquid water

Efficiently finding the minimum free energy path from steepest descent path

A parallel linear constraint solver for molecular simulation

All-atom continuous constant pH molecular dynamics with particle mesh ewald and titratable water

Molecular dynamics simulation with weak coupling to heat and material baths

Predicting crystal structures: The Parrinello-Rahman method revisited

Relaxation estimation of RMSD in molecular dynamics immunosimulations

Automatic identification of mobile and rigid substructures in molecular dynamics simulations and fractional structural fluctuation analysis

Radius of gyration as an indicator of protein structure compactness

Fast pairwise approximation of solvent accessible surface area for implicit solvent simulations of proteins on CPUs and GPUs

Visual molecular dynamics

Recent developments and applications of the MMPBSA method

GROMACS tool for high-throughput MM-PBSA calculations

Improvements to the APBS biomolecular solvation software suite

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamideinhibitors

Identification of key interactions between SARS-CoV-2 main protease and inhibitor drug candidates

Significance of root-mean-square deviation in comparing three-dimensional structures of globular proteins

Potentiality of Moringa oleifera against SARS-CoV-2: Identified by a rational computer aided drug design method

Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants

Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients

Biflavonoids from Torreyanucifera displaying SARS-CoV 3CLpro inhibition

This research was supported by the Deanship of Scientific Research, Imam Mohammad Ibn Saud Islamic University (IMSIU), Saudi Arabia, Grant No. (21-13-18-070).

The authors declare no competing interests.

Supplementary Information The online version contains supplementary material available at https:// doi. org/ 10. 1038/ s41598-022-05349-x.Correspondence and requests for materials should be addressed to S.D. or M.E.A.Z.Reprints and permissions information is available at www.nature.com/reprints.Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/.